Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

A case of hyperpigmentation and acanthosis nigricans by testosterone injections.

Karadag A, Kavala M, Demir F, Turkoğlu Z, Kartal I, Zemheri E.

Hum Exp Toxicol. 2014 Dec;33(12):1297-301. doi: 10.1177/0960327113514099.

PMID:
24505054
2.

Idiopathic eruptive macular pigmentation or acanthosis nigricans?

Joshi R, Palwade PK.

Indian J Dermatol Venereol Leprol. 2010 Sep-Oct;76(5):591. doi: 10.4103/0378-6323.69095.

3.

Current status of testosterone replacement therapy in men.

Winters SJ.

Arch Fam Med. 1999 May-Jun;8(3):257-63. Review.

PMID:
10333822
4.

Invasive breast cancer after initiation of testosterone replacement therapy in a man--a warning to endocrinologists.

Thomas SR, Evans PJ, Holland PA, Biswas M.

Endocr Pract. 2008 Mar;14(2):201-3.

PMID:
18308658
5.

Acanthosis nigricans as a local cutaneous side effect of repeated human insulin injections.

Buzási K, Sápi Z, Jermendy G.

Diabetes Res Clin Pract. 2011 Nov;94(2):e34-6. doi: 10.1016/j.diabres.2011.07.023.

PMID:
21839533
6.

Hormone substitution in male hypogonadism.

Zitzmann M, Nieschlag E.

Mol Cell Endocrinol. 2000 Mar 30;161(1-2):73-88. Review.

PMID:
10773395
7.

A case of acanthosis nigricans coexisting with mycosis fungoides.

Cheng E, Roy DB, Magro CM.

Dermatol Online J. 2015 Jul 15;21(7). pii: 13030/qt3sw2t3b8.

PMID:
26436975
8.

Case of exogenous insulin-derived acanthosis nigricans caused by insulin injections.

Yahagi E, Mabuchi T, Nuruki H, Manabe Y, Ikoma N, Ozawa A, Yamamoto N, Tanaka E, Sekido Y, Matsuyama T.

Tokai J Exp Clin Med. 2014 Mar 20;39(1):5-9.

9.

[Acral acanthosis nigricans associated with taking growth hormone].

Peña Irún A.

Semergen. 2014 May-Jun;40(4):e77-9. doi: 10.1016/j.semerg.2013.03.008. Spanish.

PMID:
23746703
10.

Paraneoplastic type of acanthosis nigricans in patient with hepatocellular carcinoma.

Kamińska-Winciorek G, Brzezińska-Wcisło L, Lis-Swiety A, Krauze E.

Adv Med Sci. 2007;52:254-6.

PMID:
18217428
11.

Reversal of polycythaemia induced by intramuscular androgen replacement using transdermal testosterone therapy.

Siddique H, Smith JC, Corrall RJ.

Clin Endocrinol (Oxf). 2004 Jan;60(1):143-5. No abstract available.

PMID:
14678301
12.

Acanthosis nigricans-like hyperpigmentation secondary to triazinate therapy.

Greenspan AH, Shupack JL, Foo SH, Wise AC.

Arch Dermatol. 1985 Feb;121(2):232-5.

PMID:
3977338
13.

Testosterone deficiency and replacement.

Howell S, Shalet S.

Horm Res. 2001;56 Suppl 1:86-92. Review.

PMID:
11786693
14.

Testosterone administration in older men.

Matsumoto AM.

Endocrinol Metab Clin North Am. 2013 Jun;42(2):271-86. doi: 10.1016/j.ecl.2013.02.011. Review.

PMID:
23702401
15.

Oral acanthosis nigricans: report of a case and comparison of oral and cutaneous pathology.

Hall JM, Moreland A, Cox GJ, Wade TR.

Am J Dermatopathol. 1988 Feb;10(1):68-73.

PMID:
3177823
16.

Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report.

Morrison BF, Reid M, Madden W, Burnett AL.

Andrology. 2013 Jul;1(4):576-82. doi: 10.1111/j.2047-2927.2013.00084.x.

17.

Eyelid involvement in acanthosis nigricans: the importance of systemic screening.

Serin D, Parlak AH, Alagöz G, Boran C, Göksügür N.

Ophthal Plast Reconstr Surg. 2005 Sep;21(5):403-4.

PMID:
16234716
18.

Hormonal therapy of male hypogonadism.

Matsumoto AM.

Endocrinol Metab Clin North Am. 1994 Dec;23(4):857-75. Review.

PMID:
7705324
19.

Coexistence of insulin-derived amyloidosis and an overlying acanthosis nigricans-like lesion at the site of insulin injection.

Kudo-Watanuki S, Kurihara E, Yamamoto K, Mukai K, Chen KR.

Clin Exp Dermatol. 2013 Jan;38(1):25-9. doi: 10.1111/j.1365-2230.2012.04373.x.

PMID:
22924529
20.

Skin reactions in a phase 3 study of a testosterone topical solution applied to the axilla in hypogonadal men.

Muram D, Melby T, Alles Kingshill E.

Curr Med Res Opin. 2012 May;28(5):761-6. doi: 10.1185/03007995.2012.681034.

PMID:
22458919

Supplemental Content

Support Center